Cardiac dysfunction in the BACHD mouse model of Huntington's disease

PLoS ONE

Volumn 11, Issue 1, 2016, Pages

  Schroeder, Analyne M ^a   Wang, Huei Bin ^a   Park, Saemi ^a   Jordan, Maria C ^b   Gao, Fuying ^a   Coppola, Giovanni ^a   Fishbein, Michael C ^b   Roos, Kenneth P ^b   Ghiani, Cristina A ^a,b   Colwell, Christopher S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; HTT PROTEIN, HUMAN; HUNTINGTIN; ISOPRENALINE; NERVE PROTEIN;

AGING; ANIMAL; APOPTOSIS; C57BL MOUSE; CARDIOMEGALY; DIAGNOSTIC IMAGING; DISEASE MODEL; DRUG EFFECTS; DRUG THERAPY; ECHOGRAPHY; FIBROSIS; GENE EXPRESSION PROFILING; GENETICS; HEART CONTRACTION; HEART LEFT VENTRICLE FUNCTION; HEART VENTRICLE; HUNTINGTON CHOREA; METABOLISM; MOUSE; MULTIPLEX POLYMERASE CHAIN REACTION; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; REAL TIME POLYMERASE CHAIN REACTION; TISSUE MICROARRAY; TRANSGENIC MOUSE; TRINUCLEOTIDE REPEAT;

ADRENERGIC BETA-AGONISTS; AGING; ANIMALS; APOPTOSIS; CARDIOMEGALY; DISEASE MODELS, ANIMAL; FIBROSIS; GENE EXPRESSION PROFILING; HEART VENTRICLES; HUNTINGTIN PROTEIN; HUNTINGTON DISEASE; ISOPROTERENOL; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MULTIPLEX POLYMERASE CHAIN REACTION; MYOCARDIAL CONTRACTION; NERVE TISSUE PROTEINS; REAL-TIME POLYMERASE CHAIN REACTION; TISSUE ARRAY ANALYSIS; TRINUCLEOTIDE REPEAT EXPANSION; ULTRASONOGRAPHY; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84991723831     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0147269     Document Type: Article

References (46)

1. Margolis RL, Ross CA. (2003) Diagnosis of Huntington disease. Clin Chem 49: 1726-1732. PMID: 14500613
2. Kuljis D, Schroeder AM, Kudo T, Loh DH, Willison DL, Colwell CS (2012) Sleep and circadian dysfunction in neurodegenerative disorders: insights from a mouse model of Huntington's disease. Minerva Pneumol 51: 93-106, 2012. PMID: 23687390
3. Saft C, Zange J, Andrich J, Müller K, Lindenberg K, (2005) Mitochondrial impairment in patients and asymptomatic mutation carriers of Huntington's disease. Mov Disord 20: 674-679.ī PMID: 15704211
4. Ciammola A, Sassone J, Alberti L, Meola G, Mancinelli E, Russo MA, et al., (2006) Increased apoptosis, Huntingtin inclusions and altered differentiation in muscle cell cultures from Huntington's disease subjects. Cell Death Differ 13: 2068-2078. PMID: 16729030
5. Chiu E, Alexander L. (1982) Causes of death in Huntington's disease. Med J Aust 1: 153.
6. Lanska DJ, Lanska MJ, Lavine L, Schoenberg BS. (1988) Conditions associated with Huntington's disease at death. A case-control study. Arch Neurol 45: 878-880. PMID: 2969233
7. Sørensen SA, Fenger K (1992) Causes of death in patients with Huntington's disease and in unaffected first degree relatives. J Med Genet 29: 911-914. PMID: 1479606
8. Sharma KR, Romano JG, Ayyar DR, Rotta FT, Facca A, Sanchez-Ramos J. (1999) Sympathetic skin response and heart rate variability in patients with Huntington disease. Arch Neurol 56: 1248-1252. PMID: 10520941
9. Andrich J, Schmitz T, Saft C, Postert T, Kraus P, Epplen JT, et al., (2002) Autonomic nervous system fu.nction in Huntington's disease. J Neurol Neurosurg Psychiatry 72: 726-731. PMID: 12023413
10. Kobal J, Meglic B, Mesec A, Peterlin B. (2004) Early sympathetic hyperactivity in Huntington's disease. Eur J Neurol 11: 842-848. PMID: 15667417
11. Bär KJ, Boettger MK, Andrich J, Epplen JT, Fischer F, Cordes J, et al., (2008) Cardiovagal modulation upon postural change is altered in Huntington's disease. Eur J Neurol 15: 869-871. doi: 10.1111/j. 1468-1331.2008.02173.x PMID: 18484985
12. Aziz NA, Anguelova GV, Marinus J, van Dijk JG, Roos RAC (2010) Autonomic symptoms in patients and pre-manifest mutation carriers of Huntington's disease. Eur J Neurol 17: 1068-1074. doi: 10.1111/ j.1468-1331.2010.02973.x PMID: 20192977
13. Kobal J, Melik Z, Cankar K, Bajrovic FF, Meglic B (2010) Autonomic dysfunction in presymptomatic and early symptomatic Huntington's disease. Acta Neurol Scand 121: 392-399. doi: 10.1111/j.1600-0404. 2009.01251.x PMID: 20047567
14. Pouladi MA, Morton AJ, Hayden MR. (2013) Choosing an animal model for the study of Huntington's disease. Nat Rev Neurosci. 14(10):708-21. doi: 10.1038/nrn3570 PMID: 24052178
15. Kudo T, Schroeder A, Loh DH, Kuljis D, Jordan MC, Roos KP, et al., (2011) Dysfunctions in circadian behavior and physiology in mouse models of Huntington's disease. Exp Neurol 228: 80-90. PMID: 21184755
16. Schroeder AM, Loh DH, Jordan MC, Roos KP, Colwell CS (2011) Baroreceptor reflex dysfunction in the BACHD mouse model of Huntington's disease. PLoS Curr 3: RRN1266. doi: 10.1371/currents. RRN1266 PMID: 22069044
17. Kiriazis H, Jennings NL, Davern P, Lambert G, Su Y, Pang T, et al., (2012) Neurocardiac dysregulation and neurogenic arrhythmias in a transgenic mouse model of Huntington's disease. J Physiol 590: 5845-5860. doi: 10.1113/jphysiol.2012.238113 PMID: 22890713
18. Mielcarek M, Inuabasi L, Bondulich MK, Muller T, Osborne GF, Franklin SA, et al., (2014) Dysfunction of the CNS-Heart Axis in Mouse Models of Huntington's Disease. PLoS Genet 10: e1004550. doi: 10. 1371/journal.pgen.1004550 PMID: 25101683
19. Mihm MJ, Amann DM, Schanbacher BL, Altschuld RA, Bauer JA, Hoyt KR (2007) Cardiac dysfunction in the R6/2 mouse model of Huntington's disease. Neurobiol Dis 2007; 25: 297-308.
20. Buonincontri G, Wood NI, Puttick SG, Ward AO, Carpenter TA, Sawiak SJ, et al., (2014) Right ventricular dysfunction in the R6/2 transgenic mouse model of Huntington's disease is unmasked by dobutamine. J Huntingt Dis 3: 25-32.
21. Wood NI, Sawiak SJ, Buonincontri G, Niu Y, Kane AD, Carpenter TA, et al., (2012) Direct evidence of progressive cardiac dysfunction in a transgenic mouse model of Huntington's disease. J Huntingt Dis doi: 10.3233/JHD-2012-120004, 2012.
22. Pattison JS, Sanbe A, Maloyan A, Osinska H, Klevitsky R, Robbins J (2008) Cardiomyocyte expression of a polyglutamine preamyloid oligomer causes heart failure. Circulation 117: 2743-2751. doi: 10. 1161/CIRCULATIONAHA.107.750232 PMID: 18490523
23. Melkani GC, Trujillo AS, Ramos R, Bodmer R, Bernstein SI, Ocorr K (2013) Huntington's disease induced cardiac amyloidosis is reversed by modulating protein folding and oxidative stress pathways in the Drosophila heart. PLoS Genet 9: e1004024. doi: 10.1371/journal.pgen.1004024 PMID: 24367279
24. Gray M, Shirasaki DI, Cepeda C, André VM, Wilburn B, Lu XH, et al., (2008) Full-length human mutant huntingtin with a stable polyglutamine repeat can elicit progressive and selective neuropathogenesis in BACHD mice. J Neurosci 28: 6182-6195.2 doi: 10.1523/JNEUROSCI.0857-08.2008 PMID: 18550760
25. Rozen S, Skaletsky H (2000) Primer3 on the WWW for general users and for biologist programmers. Methods Mol Biol 132: 365-386. PMID: 10547847
26. Ghiani CA, Starcevic M, Rodriguez-Fernandez IA, Nazarian R, Cheli VT, Chan LN, et al., (2010) The dysbindin containing complex (BLOC-1) in brain: developmental regulation, interaction with SNARE proteins and role in neurite outgrowth. Mol. Psychiatry 15 (115), 204-215.
27. Coppola G (2011) Designing, performing, and interpreting a microarray-based gene expression study. Methods Mol Biol. 793: 417-39. doi: 10.1007/978-1-61779-328-8-28 PMID: 21913117
28. Smyth GK (2004) Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol. 3: Article3 PMID: 16646809
29. Nguyen TP, Qu Z, Weiss JN (2014) Cardiac fibrosis and arrhythmogenesis: the road to repair is paved with perils. J Mol Cell Cardiol 70: 83-91. doi: 10.1016/j.yjmcc.2013.10.018 PMID: 24184999
30. Sassone J, Colciago C, Cislaghi G, Silani V, Ciammola A (2009) Huntington's disease: the current state of research with peripheral tissues. Exp Neurol 219: 385-397. PMID: 19460373
31. Cha J-HJ. (2007) Transcriptional signatures in Huntington's disease. Prog Neurobiol 83: 228-248. PMID: 17467140
32. Marchina E, Misasi S, Bozzato A, Ferraboli S, Agosti C, Rozzini L, et al., (2014) Gene expression profile in fibroblasts of Huntington's disease patients and controls. J Neurol Sci 337: 42-46. PMID: 24296361
33. Valor LM (2014) Transcription, Epigenetics and Ameliorative Strategies in Huntington's Disease: a Genome-Wide Perspective. Mol Neurobiol May 1. [Epub ahead of print].
34. Jeyaraj D, Haldar SM, Wan X, McCauley MD, Ripperger JA, Hu K, et al., (2012) Circadian rhythms govern cardiac repolarization and arrhythmogenesis. Nature 483: 96-99. doi: 10.1038/nature10852 PMID: 22367544
35. Suzuki T, Shioya T, Murayama T, Sugihara M, Odagiri F, Nakazato Y, et al., (2012) Multistep ion channel remodeling and lethal arrhythmia precede heart failure in a mouse model of inherited dilated cardiomyopathy. PloS One 7: e35353. doi: 10.1371/journal.pone.0035353 PMID: 22514734
36. Henkel DM, Glockner J, Miller WL (2012) Association of Myocardial Fibrosis, B-Type Natriuretic Peptide, and Cardiac Magnetic Resonance Parameters of Remodeling in Chronic Ischemic Cardiomyopathy. The American Journal of Cardiology 109: 390-394. doi: 10.1016/j.amjcard.2011.09.027 PMID: 22078219
37. Kapoun AM, Liang F, O'Young G, Damm DL, Quon D, White RT, et al., (2004) B-Type Natriuretic Peptide Exerts Broad Functional Opposition to Transforming Growth Factor-β in Primary Human Cardiac Fibroblasts: Fibrosis, Myofibroblast Conversion, Proliferation, and Inflammation. Circulation Research 94, 453-461. PMID: 14726474
38. Vondriska TM, Wang Y (2008) A new (heat) shocking player in cardiac hypertrophy. Circ Res. 2008 Nov 21; 103(11):1194-6.
39. Yang S, Chen C, Wang H, Rao X, Wang F, Duan Q, et al., (2012) Protective Effects of Acyl-coA Thioesterase 1 on Diabetic Heart via PPARα/PGC1α Signaling. PLoS ONE 7, e50376. doi: 10.1371/journal. pone.0050376 PMID: 23226270
40. Meléndez GC, McLarty JL, Levick SP, Du Y, Janicki JS, Brower GL, (2010) Interleukin 6 mediates myocardial fibrosis, concentric hypertrophy, and diastolic dysfunction in rats. Hypertension 56: 225-231. doi: 10.1161/HYPERTENSIONAHA.109.148635 PMID: 20606113
41. Dalrymple A, Wild EJ, Joubert R, Sathasivam K, Björkqvist M, Petersén A, et al., (2007) Proteomic profiling of plasma in Huntington's disease reveals neuroinflammatory activation and biomarker candidates. J Proteome Res 6: 2833-2840. PMID: 17552550
42. Silvestroni A, Faull RLM, Strand AD, Möller T (2009) Distinct neuroinflammatory profile in post-mortem human Huntington's disease. Neuroreport 20: 1098-1103. doi: 10.1097/WNR.0b013e32832e34ee PMID: 19590393
43. Björkqvist M, Wild EJ, Thiele J, Silvestroni A, Andre R, Lahiri N, et al., (2008) A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease. J Exp Med 205:1869-1877. doi: 10.1084/jem.20080178 PMID: 18625748
44. Aukrust P, Halvorsen B, Yndestad A, Ueland T, Øie E, Otterdal K, et al., (2008) Chemokines and Cardiovascular Risk. Arterioscler Thromb Vasc Biol 28:1909-1919. doi: 10.1161/ATVBAHA.107.161240 PMID: 18669888
45. Nickel A, Löffler J, Maack C (2013) Myocardial energetics in heart failure. Basic Res Cardiol 108: 358. doi: 10.1007/s00395-013-0358-9 PMID: 23740216
46. Lalić NM, Marić J, Svetel M, Jotić A, Stefanova E, Lalić K, et al. (2008) Glucose homeostasis in Huntington disease: abnormalities in insulin sensitivity and early-phase insulin secretion. Arch Neurol 65: 476-480. doi: 10.1001/archneur.65.4.476 PMID: 18413469